ANI Pharmaceuticals Inc (ANIP) — Capital Reinvestment Ratio

Latest as of December 2025: 0.79x

ANI Pharmaceuticals Inc (ANIP) has a Capital Reinvestment Ratio of 0.79x as of December 2025, meaning it reinvests 1% of its operating cash flow ($30.37 Million) in capital expenditures ($23.86 Million). See ANIP free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.79x
Capex / Operating Cash Flow

Operating Cash Flow

$30.37 Million
USD

Capital Expenditures

$23.86 Million
USD

Data as of

Dec 2025
Most recent filing

ANI Pharmaceuticals Inc Capital Reinvestment Ratio (2007–2025)

This chart tracks ANI Pharmaceuticals Inc's Capital Reinvestment Ratio across 12 annual periods.

Annual Capital Reinvestment Ratio for ANI Pharmaceuticals Inc (2007–2025)

Year-by-year Capital Reinvestment Ratio for ANI Pharmaceuticals Inc from 2007 to 2025. For live market cap and broader valuation context, see ANI Pharmaceuticals Inc (ANIP) total market value.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2025 0.07x $185.22 Million $13.84 Million ▼ -71.8%
2024 0.26x $64.02 Million $16.95 Million ▲ +70.2%
2023 0.16x $118.96 Million $18.51 Million ▼ -97.8%
2021 7.12x $3.32 Million $23.64 Million ▲ +59.0%
2020 4.48x $15.27 Million $68.32 Million ▲ +641.2%
2019 0.60x $45.63 Million $27.55 Million ▲ +271.1%
2018 0.16x $67.07 Million $10.91 Million ▼ -94.1%
2017 2.74x $39.42 Million $107.99 Million ▼ -49.5%
2016 5.43x $27.47 Million $149.06 Million ▲ +186.6%
2015 1.89x $17.26 Million $32.68 Million ▲ +16.7%
2014 1.62x $22.03 Million $35.75 Million ▲ +3980.5%
2007 0.04x $739.99K $29.43K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow